# US 2023/0144824 A1 · 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0144824 A1
- Document ID: US20230144824A1
- Status: Published application
- Kind: A1
- Application number: 17/793,248
- Filed: 2021-01-26
- Published: 2023-05-11
- Earliest claimed: 2020-01-27
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Liqi HE; Ashvinikumar V. GAVAI; Sanjeev GANGWAR; Qiang CONG; Yam B. POUDEL; Prasanna SIVAPRAKASAM; Christine M. TARBY; Patrice GILL; Andrew F. DONNELL; Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
- Web page: https://patentgrep.com/patent/US20230144824A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

## Claims

### Claim 1

A compound having a structure according to formula I or formula (II)
wherein
each X is independently N or CR2;
R1 is H,
(C1-C5 alkyl),
(C2-C5 alkenyl),
(C1-C8 alkanediyl)0-1(C3-C6 cycloalkyl),
(C1-C8 alkanediyl)0-1(C5-C10 spiroalkyl),
(C2-C8 alkanediyl)OH,
(C2-C8 alkanediyl)O(C1-C3 alkyl),
(C1-C4 alkanediyl)0-1(5-6 membered heteroaryl),
(C1-C4 alkanediyl)0-1phenyl,
(C1-C4 alkanediyl)CF3,
(C2-C8 alkanediyl)N[C(═O)](C1-C3 alkyl),
or
(C2-C8 alkanediyl)NRxRy;
each R2 is independently H, O(C1-C3 alkyl), S(C1-C3 alkyl), SO2(C1-C3 alkyl), C1-C3 alkyl, O(C3-C4 cycloalkyl), S(C3-C4 cycloalkyl), SO2(C3-C4 cycloalkyl), C3-C4 cycloalkyl, Cl, F, CN; or [C(═O)]0-1NRxRy;
R3 is [C(═O)]0-1H,
[C(═O)]0-1(C1-C5 alkyl),
[C(═O)]0-1(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
[C(═O)]0-1(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
[C(═O)]0-1(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
[C(═O)]0-1(C1-C4 alkanediyl)0-1O(C1-C3 alkyl),
[C(═O)]0-1(C1-C4 alkanediyl)0-1OH,
[C(═O)]0-1(C1-C4 alkanediyl)0-1NRxRy,
(C1-C4 alkanediyl)(C═O)NRxRy,
(SO2)(C1-C5 alkyl),
(SO2)(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
(SO2)(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
(SO2)(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
a 6-membered aromatic or heteroaromatic moiety, or
a 5-membered heteroaromatic moiety;
R5 is H, C1-C5 alkyl, C2-C5 alkenyl, C3-C6 cycloalkyl, halo, O(C1-C5 alkyl),
(C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl), phenyl, NH(C1-C5 alkyl), 5 or 6 membered heteroaryl,
and
Rx and Ry are independently H or C1-C3 alkyl or Rx and Ry combine with the nitrogen to which they are bonded to form a 3- to 7-membered ring;
wherein in R1, R2, R3, and R5
an alkyl, cycloalkyl, alkanediyl, bicycloalkyl, spiroalkyl, cyclic amine, 6-membered aromatic or heteroaromatic moiety, 5-membered heteroaromatic moiety or a moiety of the formula
is optionally substituted with one or more substituents selected from OH, halo, CN, (C1-C3 alkyl), O(C1-C3 alkyl), C(═O)(C1-C3 alkyl), SO2(C1-C3 alkyl), NRxRy, (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl);
and
an alkyl, alkanediyl, cycloalkyl, bicycloalkyl, spiroalkyl, or a moiety of the formula
may have a CH2 group replaced by O, SO2, CF2, C(═O), NH,
N[C(═O)]0-1(C1-C3 alkyl),
N[C(═O)]0-1(C1-C4 alkanediyl)0-1CF3,
or
N[C(═O)]0-1(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl).

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R2 is OMe.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R3 is H, Me,

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R5 is H.

### Claim 6

A compound having a structure represented by formula (Ia)
wherein
R1 is
R3 is H, Me,
and
R5 is H, Me, cyclopropyl, or Cl.

### Claim 7

A compound having a structure represented by formula (Ib)
wherein
R1 is
and
R3 is H,

### Claim 8 (depends on 1)

A method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a compound according to claim 1.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.

### Claim 10 (depends on 9)

A method according to claim 9, wherein the cancer is lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the anti-cancer immunotherapy agent is ipilimumab, nivolumab, or pembrolizumab.

### Claim 12 (depends on 1)

A compound according to claim 1, having a structure represented by formula (Ic)

### Claim 13 (depends on 1)

A compound according to claim 1, having a structure represented by formula (IIa)

### Claim 14

A compound according to formula (I′a)
wherein
R1 is
and R3 is H,

### Claim 15

A compound having a structure according to formula (I″a),
wherein
R1 is
and
R3 is

### Claim 16 (depends on 7)

A method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a compound according to claim 7.

### Claim 17 (depends on 16)

A method according to claim 16, wherein the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.

### Claim 18 (depends on 16)

A method according to claim 16, wherein the cancer is lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.

### Claim 19 (depends on 17)

A method according to claim 17, wherein the anti-cancer immunotherapy agent is ipilimumab, nivolumab, or pembrolizumab.
